Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Joseph Kwiatkowski, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by David Kwiatkowski and Heng Du.
Connection Strength

1.603
  1. A novel mouse model of hemangiopericytoma due to loss of Tsc2. Hum Mol Genet. 2018 12 15; 27(24):4169-4175.
    View in: PubMed
    Score: 0.815
  2. MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of CYR61. Oncogene. 2021 01; 40(1):112-126.
    View in: PubMed
    Score: 0.232
  3. Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion. J Exp Med. 2019 11 04; 216(11):2635-2652.
    View in: PubMed
    Score: 0.215
  4. Analysis of a Mouse Skin Model of Tuberous Sclerosis Complex. PLoS One. 2016; 11(12):e0167384.
    View in: PubMed
    Score: 0.177
  5. nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. J Clin Oncol. 2021 Oct 12; JCO2101728.
    View in: PubMed
    Score: 0.062
  6. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunol Res. 2020 08; 8(8):1075-1084.
    View in: PubMed
    Score: 0.056
  7. Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget. 2017 Sep 12; 8(39):64714-64727.
    View in: PubMed
    Score: 0.046
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.